膀胱癌靶向药厄达替尼获批上市，使膀胱癌进入精准治疗时代

The advent of the first targeted drug, Erdafitinib, has brought bladder cancer into the era of precision medicine. Erdafitinib is a once-daily oral pan-FGFR tyrosine kinase inhibitor and is also the first targeted therapy approved for metastatic bladder cancer. The FDA has approved for the first time a bladder cancer targeted therapy drug (Erdafitinib) for the treatment of patients with locally advanced or metastatic bladder cancer. Patients need to carry fibroblast growth factor receptor 3 (FGFR3) or FGFR2 gene mutations and whose disease has progressed after receiving platinum-based chemotherapy.

The efficacy of erdafitinib was demonstrated in a phase II clinical trial of 87 patients with locally advanced or metastatic bladder cancer who had disease progression after or during chemotherapy and who carried FGFR3 mutations or FGFR gene fusions. The overall response rate for treatment with FGFR kinase inhibitors was 32.2%, with 2.3% of patients having a complete response and nearly 30% having a partial response. The median duration of treatment response was 5.4 months. Responders include those who have failed to respond to drug treatment with programmed cell death protein 1 (PD1) or programmed death ligand-1 (PD-L1) inhibitors.

"I have long been committed to treating patients with metastatic urothelial cancer, but until now, there have been no new breakthroughs in this disease," lead researcher Arlene Siefker-Radtke, MD, professor of genitourinary oncology at MD Anderson Cancer Center, said in a statement. "Erdafitinib is an important new treatment that brings new hope to this small group of patients with urothelial cancer who have limited options."

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.